Showing 1381-1390 of 1655 results for "".
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- Rayner Acquires This AG, Maker of Sophi Phaco Machineshttps://modernod.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Financial terms of the deal were not disclosed. The acquisition marks a new chapter for R
- Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directorshttps://modernod.com/news/prevent-blindness-president-ceo-jeff-todd-to-lead-2024-national-health-council-board-of-directors/2482007/At the National Health Council (NHC) annual membership meeting, Jeff Todd, President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. “Jeff Todd is an excellent choice to lead our Board in 2024,” said R
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Heru Surpasses Clinical Milestone of 100,000 Eyes Examinedhttps://modernod.com/news/heru-surpasses-clinical-milestone-of-100000-eyes-examined/2481242/Heru announced that it has passed the clinical milestone of over 100,000 patient eyes that have been examined using its wearable technology since the company’s commercial launch a little over a year ago. “We are thrilled to see the rapid adoption of the Heru platform,&r
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r